stockrow
Friday 6 November 2026
Export HKPD’s income statement to Excel — free account
Cellyan Biotechnology Co., Ltd
HKPD Healthcare Medical Distribution
Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
1.50
0.14
+10.29%
Follow HKPD
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 13 | 13 | 17 | 20 | 13 | +1.7% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | 21.81 | 21.81 | 21.32 | 11.89 | 10.32 | (11.5) pt | ||||||
| EBT | — | — | — | — | — | 1 | (2) | 2 | 0 | (1) | n/m | ||||||
| EBT margin, % | — | — | — | — | — | 8.13 | 0.00 | 9.14 | 0.18 | (8.40) | (16.5) pt | ||||||
| Net income | — | — | — | — | — | 0 | 0 | 1 | 0 | (1) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 36.69 | 45.31 | 39.81 | 16.43 | n/m | |||||
| Earnings | — | — | — | — | — | — | 2.92 | 3.61 | (0.05) | (1.39) | n/m | ||||||
| Cash flow | — | — | — | — | — | — | 5.05 | (1.07) | 1.12 | (0.92) | n/m | ||||||
| Capex | — | — | — | — | — | — | (0.34) | (0.15) | (0.30) | (0.05) | (46.7%) | ||||||
| Free cash flow | — | — | — | — | — | — | 4.70 | (1.22) | 0.81 | (0.97) | n/m | ||||||
| Book value | — | — | — | — | — | 0.00 | 1.71 | 11.55 | 9.78 | 11.72 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 1 | 1 | +33.7% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.47) | 5.00 | 0.9 | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | 2 | 0 | 1 | (1) | n/m | |||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | 0 | (28.7%) | ||||||
| Free cash flow | — | — | — | — | — | — | 2 | 0 | 0 | (1) | n/m | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | 5 | 5 | 6 | 9 | +160.5% | |||||
| Net debt | — | — | — | — | — | 0 | 0 | 1 | (1) | 1 | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | 1 | 1 | 4 | 5 | 10 | +101.2% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | 31.71 | 19.49 | (0.30) | (10.21) | (10.2) pt | |||||
| ROIC | — | — | — | — | — | 395.14 | 0.00 | 19.79 | 2.11 | (6.07) | (401.2) pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 0.00 | 54.96 | (0.59) | (15.59) | (15.6) pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 19 | 27 | 11 | (23.9%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.88 | 0.75 | 1.22 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2026 · fundamentals updated 2 Nov 2026
Cellyan Biotechnology Co., Ltd vs peers in Medical Distribution (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| HSIC Henry Schein, Inc. | $9.4B | 22.8× | 21.3× | +3.95% (above 0%: growing) | +34.81% (above 0%: growing) | −7.09% (below 0%: shrinking) | 31.84% | 5.56% | Compare |
| AHG Akso Health Group Sponsored ADR | $1.1B | — (loss-making) | — (loss-making) | +263.89% (above 0%: growing) | n/m | −12,975.04% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FOCL FocalTherics | $159.3M | — (loss-making) | — (loss-making) | +38.85% (above 0%: growing) | n/m | +21.49% (above 0%: growing) | 55.59% | (60.83%) | Compare |
| COSM Cosmos Health Inc. | $29.2M | — (loss-making) | — (loss-making) | +28.76% (above 0%: growing) | n/m | +9.39% (above 0%: growing) | 7.96% | (15.41%) | Compare |
| ACH Accendra Health, Inc. | $23.0M | — (loss-making) | — (loss-making) | −10.07% (below 0%: shrinking) | n/m | −1,624.82% (below 0%: shrinking) | 42.95% | (5.73%) | Compare |
| YI 111, Inc. Sponsored ADR | $15.5M | — (loss-making) | — (loss-making) | −29.61% (below 0%: shrinking) | n/m | −185.70% (below 0%: shrinking) | 5.33% | (0.85%) | Compare |
| MEDS DataMeds AI, Inc | $5.5M | — (loss-making) | — | −77.15% (below 0%: shrinking) | n/m | −41.85% (below 0%: shrinking) | 10.24% | (412.67%) | Compare |
| HKPD Cellyan Biotechnology Co., Ltd | $3.4M | — | — | — | — | −90.45% (below 0%: shrinking) | — | — | |
| SNYRQ Synergy CHC Corp. | $1.3M | — (loss-making) | 1.6× | −32.77% (below 0%: shrinking) | n/m | −148.51% (below 0%: shrinking) | 72.29% | (10.32%) | Compare |
| Median of peers | $26.1M | — | — | −3.06% | — | −95.18% | 21.04% | (8.02%) |